Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to ...
Michael Mitchell, an associate professor of bioengineering at the University, is developing novel lipid nanoparticles that can deliver mRNA inside human cells, which could pave the way for therapies ...
Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Certest’s licensable technology includes ...
On February 2, 2026, U.S. District Court for the Eastern District of Pennsylvania Judge Joshua D. Wolson, sitting by ...
CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...
"We expect to apply this new method to many systems, including lipid nanoparticles, other pharmaceutical delivery systems and hydrated biomaterials." Dr. Robert Langer, from Massachusetts Institute of ...
Driven by the increasing need for novel LNP formulation, along with the ongoing advancements in the LNP technology, the lipid nanoparticle manufacturing market is anticipated to grow at a CAGR of 11.8 ...
Northwestern University has filed a patent infringement lawsuit against Moderna, Inc. (NASDAQ:MRNA), alleging the pharmaceutical company used the university’s lipid nanoparticle (LNP) technology ...
insights from industryYoann LefeuvreDirector of Product ManagementMicrotrac In this interview, AZoNano speaks with Yoann Lefeuvre, Director of Product Management at Microtrac. Yoann discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results